WO1987005517A1 - Sels de metaux lourds de l'acide hyaluronique utiles en tant qu'agents antimicrobiens - Google Patents

Sels de metaux lourds de l'acide hyaluronique utiles en tant qu'agents antimicrobiens Download PDF

Info

Publication number
WO1987005517A1
WO1987005517A1 PCT/US1987/000549 US8700549W WO8705517A1 WO 1987005517 A1 WO1987005517 A1 WO 1987005517A1 US 8700549 W US8700549 W US 8700549W WO 8705517 A1 WO8705517 A1 WO 8705517A1
Authority
WO
WIPO (PCT)
Prior art keywords
silver
hyaluronate
compound
effective amount
hyaluronic acid
Prior art date
Application number
PCT/US1987/000549
Other languages
English (en)
Inventor
Abraham Nimrod
Benjamin Greenman
Original Assignee
Bio-Technology General Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/840,419 external-priority patent/US4746504A/en
Priority claimed from US07/023,666 external-priority patent/US4784991A/en
Application filed by Bio-Technology General Corp. filed Critical Bio-Technology General Corp.
Publication of WO1987005517A1 publication Critical patent/WO1987005517A1/fr
Priority to DK597487A priority Critical patent/DK597487A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/14—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
    • A01N43/16—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Definitions

  • Hyaluronic acid has been isolated from the various biological sources, as described above, including microbial broth. The isolation and characterization of hyaluronic acid has been described by Meyer et al., J. Biol. Chem. 107,629 (1934); J. Biol. Chem. 114,689 (1936), and has recently been reviewed in Methods in Enzymol. 28, 73 (1972). The structure of hyaluronic acid was elucidated by Weissman et al., J. Am. Chem. Soc. 76, 1753 (1954) and Meyer, Fed. Proc. 17, 1075 (1958). Other publications such as, U.S. Patent No. 4,141,973, February 27, 1979 by E.A. Balazs, concerned the production and purification of hyaluronic acid from the sources such as animal connective tissue.
  • silver compounds produce thei r antimicrobial effect s by the time-dependent rel ease of silver ions and their effectiveness is directly related to the constant presence of the free ions in the tissues.
  • simple silver salts such as silver nitrate
  • silver nitrate as an antibacterial agent has been limited by the requirement of frequent applications to achieve effective concentrations of the silver ions (10-20 ug/ml) .
  • the invention is al so directed to methods of inhibiting microbial growth util izing these heavy metal salts.
  • the present invention concerns methods of producing silver hyaluronate, compositions containing silver hyal uronate, and the treatment of wounds, burns and infections, especial ly sof t-tissue infections and gonoccocal opthalmalogical infections, with silver hyaluronate.
  • Heavy metal sal ts of hyaluronic acid may be incorporated into compositions, such as pharmaceutical compositions containing an effective amount of the heavy metal sal t, e. g. , silver hyaluronate or gol d hyaluronate, and a pharmaceutically acceptable ca rrier.
  • compositions such as pharmaceutical compositions containing an effective amount of the heavy metal sal t, e. g. , silver hyaluronate or gol d hyaluronate, and a pharmaceutically acceptable ca rrier.
  • This invention also concerns compositions containing heavy metal salts of radioactively labelled hyaluronic acid.
  • the silver hyal uronate is prepared in the absence of l ight and the aqueous sodium hyaluronate and aqueous silver nitrate mixture is shaken for a suff icient period of time, ordinarily several hours, to formaqueous silver hyal uronate solution.
  • the aqueous silver hyaluronate sol ution is then treated to effect precipitation of the silver hyaluronate which may be recovered by rinsing the silver hyaluronate precipitate with ethanol , drying the rinsed precipitate wi th nitrogen and further drying the nitrogen-dried precipitate by high vacuum drying.
  • the other heavy metal salts of hyaluronic acid may be prepared by methods analogous to the preparation of silver hyaluronate.
  • the heavy metal sal ts of hyaluronic acid and compositions containing same are useful as antimicrobial agents.
  • microbial growth may be inhibited by contacting the microbes with an effective amount of silver hyaluronate.
  • Silver hyaluronate may al so be used for treating burns, wounds, soft tissue infections, for example, gonoccocal opthalmalogical infections or sepsis by topically applying an effective amount of the silver hyaluronate to the site of the burn, wound, soft tissue infection or infection f rom which the sepsis stems.
  • Silver hyaluronate compositions are also used for treating keratitis infections.
  • Hyaluronic acid is a maj or constitutent of connective tissue, body fluids and skin, and hence is absolutely non-immunogenic. Due to thei r large size (M .W. 1.5x10 6 Daltons) , HA salts form viscous solutions, and after inj ection into the tissues the polysaccharide diffuses extremely slowly from the injection site.
  • Minimal Inhibitory Concentration was tested on eight species of bacteria isolated from hospitalized patients. The eight species are E. coli; Seratia; Pseudomonas; Proteus; K. pneumoniae; Acinobacter; C. albicans; and M. morgani.
  • a white-colored precipitate probably AgCl, appears immediately when the Ag-hyaluronate comes in contact with culture media or serum.
  • the scoring resul ts were analyzed statistically by the two tailed Wilcoxon rank sum test.
  • AgHA was shown to have an effective therapeutic effect against the viscous bacteria Pseudomonas aeruginosa. in vivo.
  • the use of such a preparation on i ts own or in conjunction with the commonly-used antibiotics might prove highly benef icial in the topical treatment of bacterial keratiti s .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sels de métaux lourds de l'acide hyaluronique et notamment sels d'argent, d'or, de cérium et de tungstène de l'acide hyaluronique. Ces sels de métaux lourds de l'acide hyaluronique sont utiles en tant qu'agents antimicrobiens. L'hyaluronate d'or peut également être utilisé pour traiter l'arthrite. L'invention se rapporte également à des procédés de production de sels d'argent de l'acide hyaluronique ainsi qu'à des compositions contenant l'hyaluronate d'argent ou l'hyaluronate d'or. L'invention se rapporte également à des sels de métaux lourds possédant des moitiés d'hyaluronates marquées radioactivement.
PCT/US1987/000549 1986-03-14 1987-03-13 Sels de metaux lourds de l'acide hyaluronique utiles en tant qu'agents antimicrobiens WO1987005517A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK597487A DK597487A (da) 1986-03-14 1987-11-13 Hyaluronsyre-tungmetalsalte til anvendelse som mikrobielle midler

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US06/840,419 US4746504A (en) 1986-03-14 1986-03-14 Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
US840,419 1986-03-14
US1947487A 1987-02-26 1987-02-26
US019,474 1987-02-26
US07/023,666 US4784991A (en) 1986-03-14 1987-03-09 Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
US023,666 1987-03-09

Publications (1)

Publication Number Publication Date
WO1987005517A1 true WO1987005517A1 (fr) 1987-09-24

Family

ID=27361231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/000549 WO1987005517A1 (fr) 1986-03-14 1987-03-13 Sels de metaux lourds de l'acide hyaluronique utiles en tant qu'agents antimicrobiens

Country Status (4)

Country Link
EP (1) EP0259485A4 (fr)
AU (1) AU600483B2 (fr)
CA (1) CA1291123C (fr)
WO (1) WO1987005517A1 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356435A1 (fr) * 1987-03-19 1990-03-07 Arthropharm Pty Ltd Composes et compositions anti-inflammatoires.
GR900100137A (en) * 1989-02-24 1991-06-28 Richter Gedeon Vegyeszet Novel compositions containing hyaluronic acid associates and a process for preparing same
WO1992020716A1 (fr) * 1991-05-11 1992-11-26 Basf Aktiengesellschaft Hyaluronates ferriques
WO1997011710A1 (fr) * 1995-09-28 1997-04-03 Sangstat Medical Corporation Utilisation d'acide hyaluronique en qualite d'agent immunosuppresseur
WO1998010773A1 (fr) * 1996-09-12 1998-03-19 Richter Gedeon Vegyészeti Gyár Rt. Compositions pharmaceutiques a activite antimicrobienne
WO2000053194A1 (fr) 1999-03-10 2000-09-14 Takata Seiyaku Co., Ltd. Medicaments contre les affections articulaires
EP1311276A1 (fr) * 2000-07-31 2003-05-21 Dermal Research Laboratories, Inc. Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes
GB2392913A (en) * 2002-09-11 2004-03-17 Johnson & Johnson Medical Ltd Complex of an anionic polysaccharide with silver
WO2004024197A1 (fr) 2002-09-11 2004-03-25 Johnson & Johnson Medical Limited Materiaux pour pansements contenant des complexes composes de polysaccharides anioniques et d'argent
GB2402880A (en) * 2003-06-20 2004-12-22 Johnson & Johnson Medical Ltd Antimicrobial silver complexes
BG64458B1 (bg) * 1997-04-29 2005-03-31 Richter Gedeon Vegyeszeti Gyar Rt. Използване на цинков хиалуронат срещу пептична язва
WO2009063291A1 (fr) * 2007-11-13 2009-05-22 Bio-Technology General (Israel) Ltd. Procédé de stérilisation par filtration à l'état dilué pour des biopolymères viscoélastiques
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
EP2289522A1 (fr) 2009-08-14 2011-03-02 Holy Stone Healthcare Co.,Ltd. Utilisation d'acide hyaluronique pour le traitement d'ulcers gastro-duodenaux
EP2292243A1 (fr) 2009-08-14 2011-03-09 Holy Stone Healthcare Co.,Ltd. Mélange d'acide hyaluronique pour traiter et empêcher les maladies intestinales inflammatoires
US8124826B2 (en) 2003-11-18 2012-02-28 Systagenix Wound Management (Us), Inc. Antioxidant and antimicrobial wound dressing materials
ITPD20100349A1 (it) * 2010-11-19 2012-05-20 Fidia Farmaceutici Composizioni farmaceutiche ad attivita' antibatterica e cicatrizzante
CN102552309A (zh) * 2010-12-15 2012-07-11 北京理工大学 一种透明质酸金的用途及其制备方法
KR101173962B1 (ko) * 2003-06-20 2012-08-16 존슨 앤드 존슨 메디칼 리미티드 산화방지성 상처 드레싱 물질
EP2543357A1 (fr) 2011-07-07 2013-01-09 Holy Stone Healthcare Co.,Ltd. Composition pour une utilisation dans le traitement et la prévention d'une maladie liée à l'inflammation
EP2545925A1 (fr) 2011-07-12 2013-01-16 Holy Stone Healthcare Co.,Ltd. Compositions comprenant de l'acide hyaluronique pour le traitement et la prévention de maladies liées aux muqueuses
WO2013017807A1 (fr) 2011-08-04 2013-02-07 Petcare Innovation Composition antiseptique
CZ303722B6 (cs) * 2012-01-16 2013-04-03 Contipro Biotech S.R.O. Kyselina hyaluronová znacená tritiem, zpusob znacení kyseliny hyaluronové tritiem a její pouzití
US8425926B2 (en) 2003-07-16 2013-04-23 Yongxing Qiu Antimicrobial medical devices
WO2013121001A1 (fr) 2012-02-17 2013-08-22 Kimflexor, S.L. Sels d'argent et d'or de glycosaminoglycane partiellement dépolymérisés
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
WO2014131974A1 (fr) 2013-02-28 2014-09-04 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
CN112500505A (zh) * 2020-11-19 2021-03-16 徐州医科大学 一种高分子银复合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172128A (en) * 1975-03-26 1979-10-23 Erhard Thiele Process of degrading and regenerating bone and tooth material and products
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4487865A (en) * 1983-12-15 1984-12-11 Biomatrix, Inc. Polymeric articles modified with hyaluronate
US4605691A (en) * 1984-12-06 1986-08-12 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172128A (en) * 1975-03-26 1979-10-23 Erhard Thiele Process of degrading and regenerating bone and tooth material and products
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4487865A (en) * 1983-12-15 1984-12-11 Biomatrix, Inc. Polymeric articles modified with hyaluronate
US4605691A (en) * 1984-12-06 1986-08-12 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Arthritis and Rheumatism 25: (12), issued 1982, (BETTS et al.), "Effect of Metal Chelators and Antiinflammatory Drugs on the Degradation of Hyaluronic Acid, pages 1469-1476. *
Biochemical and Biophysical Research Communications 74(2), issued 1977, (FIGUEROA et al.), "Chu2+-Hyaluronic Acid Complex: Spectrophotometric Detection", pages 460-465. *
Biopolymers 17, issued 1978, (FIGUEROA et al.), "Circular Dichroism Studies of Copper (II).- Hyaluronic Acid Complex in Relation to Conformation of the Polymer" pages 2415-2426. *
Connective Tissue Res. 6(2), issued 1978, (ATKINS et al.) "Hyaluronic Acid Conformations Observed for Various Salt Forms in the Crystaline Phase, page 116. *
Current Eye Research 3(8), issued 1984, (LIU et al.), "Inhibition of Oxidative Degredation of Hyaluronic Acid by Uric Acid", pp 1049-1053. *
Graefe's Arch. Clin. Exp. Ophthalmol. 218, issued 1982, (SCHMUT et al.), "Preparation of Gels from Hyaluronate Solutions", pages 311-314. *
J. Biol. Chem., issued 1956, (VOURAS et al.), "The Outer Sphere Association of Chondroitin Sulfate with Polyvalent Complex Cations", pages 792-795. *
See also references of EP0259485A4 *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356435A1 (fr) * 1987-03-19 1990-03-07 Arthropharm Pty Ltd Composes et compositions anti-inflammatoires.
EP0356435A4 (fr) * 1987-03-19 1990-06-26 Arthropharm Pty Ltd Composes et compositions anti-inflammatoires.
GR900100137A (en) * 1989-02-24 1991-06-28 Richter Gedeon Vegyeszet Novel compositions containing hyaluronic acid associates and a process for preparing same
LT3806B (en) 1989-02-24 1996-03-25 Richter Gedeon Vegyeszet Hyaluronic acid associates, composition containing them, process for preparing the composition, process for preparing zinc hyaluronate aqueous solution
WO1992020716A1 (fr) * 1991-05-11 1992-11-26 Basf Aktiengesellschaft Hyaluronates ferriques
AU719365B2 (en) * 1995-09-28 2000-05-04 Sangstat Medical Corporation Use of hyaluronic acid as an immunosuppressant
US6013641A (en) * 1995-09-28 2000-01-11 Sangstat Medical Corporation Use of hyaluronic acid as an immunosuppressant
WO1997011710A1 (fr) * 1995-09-28 1997-04-03 Sangstat Medical Corporation Utilisation d'acide hyaluronique en qualite d'agent immunosuppresseur
WO1998010773A1 (fr) * 1996-09-12 1998-03-19 Richter Gedeon Vegyészeti Gyár Rt. Compositions pharmaceutiques a activite antimicrobienne
BG64458B1 (bg) * 1997-04-29 2005-03-31 Richter Gedeon Vegyeszeti Gyar Rt. Използване на цинков хиалуронат срещу пептична язва
WO2000053194A1 (fr) 1999-03-10 2000-09-14 Takata Seiyaku Co., Ltd. Medicaments contre les affections articulaires
EP1166788A1 (fr) * 1999-03-10 2002-01-02 Takata Seiyaku Kabushiki Kaisha Medicaments contre les affections articulaires
EP1166788A4 (fr) * 1999-03-10 2007-10-10 Takata Seiyaku Kabushiki Kaish Medicaments contre les affections articulaires
EP1311276A4 (fr) * 2000-07-31 2007-09-12 Dermal Res Lab Inc Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes
EP1311276A1 (fr) * 2000-07-31 2003-05-21 Dermal Research Laboratories, Inc. Procedes servant a prevenir ou a traiter des maladies et des etats au moyen de glucides complexes
US8367642B2 (en) 2000-07-31 2013-02-05 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
GB2392913B (en) * 2002-09-11 2007-04-04 Johnson & Johnson Medical Ltd Wound dressings comprising complexes of oxidised celluloses with silver
US8461410B2 (en) 2002-09-11 2013-06-11 Ethicon, Inc. Wound dressing materials comprising complexes of anionic polysaccharides with silver
GB2392913A (en) * 2002-09-11 2004-03-17 Johnson & Johnson Medical Ltd Complex of an anionic polysaccharide with silver
WO2004024197A1 (fr) 2002-09-11 2004-03-25 Johnson & Johnson Medical Limited Materiaux pour pansements contenant des complexes composes de polysaccharides anioniques et d'argent
GB2402880B (en) * 2003-06-20 2008-01-23 Johnson & Johnson Medical Ltd Antimicrobial compositions comprising silver
GB2402880A (en) * 2003-06-20 2004-12-22 Johnson & Johnson Medical Ltd Antimicrobial silver complexes
KR101173962B1 (ko) * 2003-06-20 2012-08-16 존슨 앤드 존슨 메디칼 리미티드 산화방지성 상처 드레싱 물질
US8425926B2 (en) 2003-07-16 2013-04-23 Yongxing Qiu Antimicrobial medical devices
US10143771B2 (en) 2003-11-18 2018-12-04 Kci Usa, Inc. Antioxidant and antimicrobial wound dressing materials
US8124826B2 (en) 2003-11-18 2012-02-28 Systagenix Wound Management (Us), Inc. Antioxidant and antimicrobial wound dressing materials
US20150352244A1 (en) * 2003-11-18 2015-12-10 Kci Usa, Inc. Antioxidant and antimicrobial wound dressing materials
US9896518B2 (en) 2007-11-13 2018-02-20 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers
WO2009063291A1 (fr) * 2007-11-13 2009-05-22 Bio-Technology General (Israel) Ltd. Procédé de stérilisation par filtration à l'état dilué pour des biopolymères viscoélastiques
AU2008322629B2 (en) * 2007-11-13 2013-05-16 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers
EP3842046A1 (fr) 2009-08-14 2021-06-30 Holy Stone Healthcare Co.,Ltd. Mélange d'acide hyaluronique permettant de traiter et d'empêcher les maladies intestinales inflammatoires
EP2292243A1 (fr) 2009-08-14 2011-03-09 Holy Stone Healthcare Co.,Ltd. Mélange d'acide hyaluronique pour traiter et empêcher les maladies intestinales inflammatoires
EP2289522A1 (fr) 2009-08-14 2011-03-02 Holy Stone Healthcare Co.,Ltd. Utilisation d'acide hyaluronique pour le traitement d'ulcers gastro-duodenaux
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
AU2011330855B2 (en) * 2010-11-19 2016-09-15 Fidia Farmaceutici S.P.A. Compositions with antibacterial and wound healing activity
WO2012066447A1 (fr) * 2010-11-19 2012-05-24 Fidia Farmaceutici S.P.A. Compositions ayant une activité antibactérienne et de cicatrisation
ITPD20100349A1 (it) * 2010-11-19 2012-05-20 Fidia Farmaceutici Composizioni farmaceutiche ad attivita' antibatterica e cicatrizzante
US9265793B2 (en) 2010-11-19 2016-02-23 Fidia Farmaceutici S.P.A Compositions with antibacterial and wound healing activity
CN102552309A (zh) * 2010-12-15 2012-07-11 北京理工大学 一种透明质酸金的用途及其制备方法
EP2543357A1 (fr) 2011-07-07 2013-01-09 Holy Stone Healthcare Co.,Ltd. Composition pour une utilisation dans le traitement et la prévention d'une maladie liée à l'inflammation
US10709731B2 (en) 2011-07-12 2020-07-14 Aihol Corporation Materials for treating and preventing mucosa related disease
EP2545925A1 (fr) 2011-07-12 2013-01-16 Holy Stone Healthcare Co.,Ltd. Compositions comprenant de l'acide hyaluronique pour le traitement et la prévention de maladies liées aux muqueuses
WO2013017807A1 (fr) 2011-08-04 2013-02-07 Petcare Innovation Composition antiseptique
WO2013017808A1 (fr) 2011-08-04 2013-02-07 Dermaconcept Jmc Composition antiseptique.
CZ303722B6 (cs) * 2012-01-16 2013-04-03 Contipro Biotech S.R.O. Kyselina hyaluronová znacená tritiem, zpusob znacení kyseliny hyaluronové tritiem a její pouzití
WO2013121001A1 (fr) 2012-02-17 2013-08-22 Kimflexor, S.L. Sels d'argent et d'or de glycosaminoglycane partiellement dépolymérisés
JP2015507070A (ja) * 2012-02-17 2015-03-05 キムフレクサー エセ．エレ． 部分的に解重合したグリコサミノグリカン銀及び金塩
CN104125964A (zh) * 2012-02-17 2014-10-29 金弗莱克瑟有限公司 部分解聚的糖胺聚糖银盐和金盐
WO2014131974A1 (fr) 2013-02-28 2014-09-04 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
EP3287171A1 (fr) 2013-02-28 2018-02-28 Laboratoires Thea S.A.S. Composition dermatologique antimicrobienne topique pour une utilisation en ophtalmologie
CN112500505A (zh) * 2020-11-19 2021-03-16 徐州医科大学 一种高分子银复合物及其制备方法和应用

Also Published As

Publication number Publication date
EP0259485A1 (fr) 1988-03-16
CA1291123C (fr) 1991-10-22
AU7206887A (en) 1987-10-09
AU600483B2 (en) 1990-08-16
EP0259485A4 (fr) 1988-07-29

Similar Documents

Publication Publication Date Title
AU600483B2 (en) Heavy metal salts of hyaluronic acid
JP2613605B2 (ja) 抗菌物質として有効なヒアルロン酸の重金属塩
US4784991A (en) Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
AU2002303438B2 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
US5079236A (en) Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
US6348190B1 (en) Pharmaceutical compositions with antimicrobial activity
US8263763B2 (en) Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound
AU705289B2 (en) Use of hyaluronic acid for the treatment of cystitis
US6537978B1 (en) Oral administration of effective amounts of forms of hyaluronic acid
HU220758B1 (hu) Eljárás hialuronsavat és nem szteroid gyulladásgátlót tartalmazó, rák kezelésére alkalmas gyógyászati készítmények előállítására
JPH0152370B2 (fr)
WO2000053194A1 (fr) Medicaments contre les affections articulaires
EP1698641B1 (fr) Sulfate de cellulose, ses sels et agent thérapeutique pour la dermatite
CN104125964B (zh) 部分解聚的糖胺聚糖银盐和金盐
WO2000030609A1 (fr) Formulations ophtalmiques aqueuses utilisables en tant que larmes artificielles possedant une activite antimicrobienne
HUT76895A (en) Use of hyaluronic acid for preparing pharmaceutical compns. for treatment of disease and conditions associated with macrophage infiltration
US8568711B2 (en) Antimicrobial compositions
Novak et al. The tolerance and safety of intravenously administered benzyl alcohol in methylprednisolone sodium succinate formulations in normal human subjects
JPH0469342A (ja) 水性医薬製剤
Gorman et al. Decrease in adherence of bacteria and yeasts to human mucosal epithelial cells by noxythiolin in vitro
US5472950A (en) Compositions containing cobalt hyaluronic acid complex
RU2797957C1 (ru) Антисептическая комбинация, антисептическая фармацевтическая композиция и их применение
RU2774622C1 (ru) Антисептическая комбинация, антисептическая фармацевтическая композиция и их применение
US20150064129A1 (en) Wound healing composition
EP0888770A1 (fr) Compositions pharmaceutiques contenant des polysaccharides cationiques et des médicaments cationiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987902255

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987902255

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1987902255

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1987902255

Country of ref document: EP